Form 4: Beta Bionics CCO Sells Shares Under 10b5-1 Plan

Beta Bionics' Chief Commercial Officer, Mark Hopman, sold 353 shares of common stock for $11.57 per share under a pre-arranged 10b5-1 plan.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported a sale of common stock.
• The transaction involved the disposition of 353 shares of common stock.
• The shares were sold at a price of $11.57 per share.
• The sale occurred on March 4, 2026.
• Following this transaction, Mark Hopman beneficially owns 139,133 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 Plan, which was adopted on May 13, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale of shares by the Chief Commercial Officer was conducted under a pre-arranged 10b5-1 plan, indicating a scheduled transaction for personal financial management rather than a reaction to new company-specific information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that routine insider sales executed under a Rule 10b5-1 plan are common practice for corporate executives to manage personal finances and diversify holdings, often pre-scheduled to avoid accusations of trading on material non-public information. Such transactions are generally not indicative of management's sentiment regarding the company's immediate prospects or broader industry trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled insider sale under a 10b5-1 plan, not typically signaling a change in company fundamentals or management confidence.

Key Dates

Recommendation

The transaction reported is a routine insider sale executed under a Rule 10b5-1 plan, which was adopted well in advance of the sale date. Such pre-scheduled sales are typically for personal financial planning and diversification, and generally do not reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, this filing alone does not provide a basis for a 'buy' or 'sell' recommendation, warranting a 'hold' stance as investors should rely on broader company performance and market analysis.

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Commercial Officer, Mark Hopman